Subanalysis | Number of guidelines (%) | Domain scores (mean±SD, %) | |||||
Scope and purpose | Stakeholder involvement | Rigour of development | Clarity of presentation | Applicability | Editorial independence | ||
Developing organisation | |||||||
Chinese Medical Diabetes Association | 60 (61.1%) | 54.9±6.8 | 31.7±8.3 | 20.7±9.2 | 58.4±8.4 | 20.3±8.6 | 1.3±4.1 |
Specially formed group* | 18 (18.4%) | 55.1±8.0 | 32.8±13.9 | 19.8±15.8 | 56.2±12.1 | 17.9±10.9 | 2.6±6.5 |
National Health and Family Planning Commission | 2 (2.1%) | 45.4±9.2 | 27.8±2.6 | 13.5±17.2 | 41.7±32.7 | 13.9±0.0 | 0.0±0.0 |
Ministry of Public Health | 1 (1.0%) | 44.4 | 16.7 | 4.2 | 29.6 | 0.0 | 0.0 |
Hospitals | 1 (1.0%) | 59.3 | 31.5 | 21.5 | 59.3 | 16.7 | 0.0 |
Collaboration of two or more organisations | 14 (14.3%) | 56.1±5.5 | 33.5±5.3 | 19.7±9.8 | 56.0±12.0 | 18.2±7.2 | 0.8±3.0 |
Others | 2 (2.1%) | 52.8±3.9 | 39.8±11.8 | 25.0±7.9 | 53.7±10.5 | 18.8±6.9 | 8.3±11.8 |
P value | 0.36 | 0.54 | 0.77 | 0.18 | 0.48 | 0.35 | |
Type of guidelines | |||||||
Diagnosis and treatment | 27 (27.6) | 55.8±7.9 | 30.3±6.3 | 18.6±6.6 | 59.2±7.9 | 22.3±9.5 | 1.6±4.8 |
Treatment | 22 (22.4%) | 54.5±7.8 | 33.6±10.8 | 22.4±14.8 | 55.6±14.1 | 20.3±9.0 | 0.6±3.0 |
Management | 14 (14.3%) | 53.4±6.0 | 31.0±6.3 | 18.3±6.9 | 56.1±10.3 | 14.9±5.3 | 1.2±4.5 |
Prevention and treatment | 9 (9.2%) | 54.9±3.6 | 29.2±6.5 | 20.0±3.8 | 61.3±3.0 | 19.6±9.1 | 1.2±3.5 |
Technology† | 6 (6.1%) | 51.2±2.2 | 38.9±6.6 | 18.6±6.9 | 53.4±10.0 | 16.7±4.6 | 2.8±6.8 |
Medication‡ | 5 (5.1%) | 56.7±7.9 | 34.8±7.6 | 22.5±7.5 | 58.1±11.2 | 19.2±9.1 | 0.0±0.0 |
Prevention | 1 (1.0%) | 68.5 | 37.0 | 24.3 | 64.8 | 29.2 | 0.0 |
Healthcare | 1 (1.0%) | 59.3 | 14.8 | 7.6 | 40.7 | 15.3 | 0.0 |
Comprehensive§ | 13 (13.3%) | 54.4±6.6 | 33.0±14.8 | 22.2±17.9 | 54.1±14.6 | 15.8±8.9 | 4.1±6.5 |
P value | 0.49 | 0.25 | 0.84 | 0.52 | 0.19 | 0.64 | |
Publication year | |||||||
2009 | 3 (3.0%) | 59.9±7.7 | 26.5±8.8 | 15.7±6.5 | 53.1±10.9 | 22.2±2.8 | 0.0±0.0 |
2010 | 7 (7.1%) | 52.1±8.1 | 28.8±6.2 | 14.7±4.3 | 50.8±10.8 | 13.5±11.9 | 2.4±6.3 |
2011 | 23 (23.5%) | 56.2±6.5 | 32.3±7.3 | 21.2±6.3 | 60.5±8.1 | 22.3±8.6 | 0.5±2.3 |
2012 | 13 (13.3%) | 53.3±6.2 | 34.5±12.9 | 23.5±17.6 | 54.6±11.6 | 16.0±7.2 | 3.2±6.2 |
2013 | 10 (10.2%) | 53.9±8.5 | 27.8±6.3 | 15.4±4.6 | 54.3±10.8 | 19.4±11.2 | 1.7±5.3 |
2014 | 12 (12.2%) | 56.8±7.8 | 32.7±8.4 | 19.6±5.3 | 60.6±6.8 | 22.7±9.7 | 1.4±4.8 |
2015 | 9 (9.2%) | 54.1±5.6 | 31.1±5.9 | 22.8±5.4 | 61.7±5.4 | 20.4±7.6 | 1.2±3.7 |
2016 | 14 (14.3%) | 53.0±6.1 | 32.1±7.5 | 18.6±9.5 | 53.2±15.1 | 16.1±2.9 | 0.8±3.0 |
2017 | 7 (7.1%) | 56.3±8.0 | 38.6±17.7 | 25.4±24.5 | 56.3±16.1 | 17.3±9.8 | 4.4±7.5 |
P value | 0.58 | 0.38 | 0.42 | 0.20 | 0.13 | 0.59 | |
Western medicine or traditional Chinese medicine | |||||||
Western medicine | 78 (79.6%) | 53.7±6.7 | 31.2±7.3 | 18.9±7.3 | 56.5±11.9 | 18.2±8.3 | 1.3±4.4 |
Traditional Chinese medicine | 14 (14.3%) | 58.6±5.9 | 31.1±7.5 | 19.9±4.8 | 58.7±5.6 | 21.8±9.7 | 1.6±4.0 |
Integrated medicine | 6 (6.1%) | 59.3±7.9 | 44.4±22.1 | 36.9±31.5 | 60.8±1.4 | 24.3±8.5 | 4.6±7.2 |
P value | 0.01 | 0.002 | 0.001 | 0.53 | 0.11 | 0.23 | |
Participation of methodologists in guideline development | |||||||
Methodologists involved | 27 (27.6%) | 55.6±7.2 | 36.9±11.4 | 25.2±16.8 | 58.3±10.0 | 19.8±6.6 | 1.4±4.2 |
Not reported | 71 (72.4%) | 54.6±6.9 | 30.2±7.6 | 18.3±6.6 | 56.4±11.3 | 19.0±9.4 | 1.6±4.7 |
P value | 0.52 | 0.01 | 0.048 | 0.45 | 0.67 | 0.77 | |
External funding | |||||||
No reported external funding | 85 (86.7%) | 55.2±6.6 | 32.3±8.3 | 19.7±9.6 | 56.6±11.4 | 19.7±8.3 | 0.5±2.6 |
External funding reported | 13 (13.3%) | 52.6±8.7 | 30.6±14.4 | 23.2±17.0 | 58.8±6.8 | 15.9±10.7 | 8.8±7.5 |
P value | 0.19 | 0.54 | 0.25 | 0.31 | 0.13 | 0.001 | |
Indexation in Chinese Sciences Citation Database (CSCD) | |||||||
Indexed in CSCD | 60 (61.2%) | 54.0±7.0 | 32.4±8.6 | 20.0±10.4 | 56.9±10.6 | 17.8±8.2 | 2.0±5.2 |
Not indexed in CSCD | 37 (37.8%) | 56.1±6.8 | 32.0±10.0 | 20.8±11.5 | 57.4±11.4 | 21.5±9.2 | 1.0±3.4 |
P value | 0.14 | 0.65 | 0.82 | 0.98 | 0.46 | 0.27 | |
Version | |||||||
Original | 81 (82.7%) | 54.8±7.3 | 31.9±9.3 | 19.9±11.5 | 56.2±0.1 | 18.9±0.1 | 1.9±5.0 |
Updated | 17 (17.3%) | 55.0±4.8 | 32.9±9.2 | 21.4±6.6 | 60.2±9.4 | 20.7±6.9 | 0.0±0.0 |
P value | 0.14 | 0.43 | 0.38 | 0.30 | 0.20 | 0.00 |
*Groups specifically formed for developing the guideline; members were staff from different hospitals.
†Refers to guidelines about the use of medical equipment, eg, insulin injection needle.
‡Refers to guidelines about the use of specific drugs, eg, insulin.
§Refers to guidelines covering more than two types of guidelines.